May 19, 2025
Compugen Reports First Quarter 2025 Results
May 13, 2025
Compugen Announces Leadership Transitions Effective September 2025
May 05, 2025
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025
Mar 26, 2025
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
Feb 18, 2025
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
Feb 04, 2025
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Jan 08, 2025
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Nov 05, 2024
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
Oct 29, 2024
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Oct 07, 2024
Compugen to Present New Clinical Data at SITC 2024
Sep 09, 2024
Compugen to Present at Single Cell Genomics 2024 Conference
Aug 29, 2024
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 06, 2024
Compugen Reports Second Quarter 2024 Results
Jul 29, 2024
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
Jul 23, 2024
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
Jun 17, 2024
Compugen to Present at Upcoming Antibody Industrial Symposium
May 30, 2024
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
May 20, 2024
Compugen Reports First Quarter 2024 Results
May 16, 2024
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
May 15, 2024
Compugen Appoints David Silberman as Chief Financial Officer